News from provention bio, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Sep 25, 2019, 07:00 ET Provention Bio to Present at the 2019 Cantor Global Healthcare Conference

Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Sep 24, 2019, 07:00 ET Provention Bio Reiterates Regulatory Strategy for PRV-031 and Announces Completion of Follow-on Financing

Provention Bio, Inc., (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Sep 18, 2019, 20:26 ET Provention Bio Announces Pricing of $40 Million Public Offering of Common Stock

Provention Bio, Inc., (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Sep 18, 2019, 16:14 ET Provention Bio Announces Proposed Public Offering of Common Stock

Provention Bio, Inc., (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Sep 05, 2019, 07:00 ET Provention Bio to Present at the H.C. Wainwright 21st Annual Global Investment Conference

Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Aug 20, 2019, 07:00 ET Provention Bio Announces Key Addition to its Leadership Team

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Aug 08, 2019, 07:00 ET Provention Bio Initiates Phase 1b/2a PREVAIL Clinical Trial Evaluating PRV-3279 in Lupus

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease,...

Aug 06, 2019, 07:00 ET Provention Bio Reports Second Quarter 2019 Financial Results

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Aug 05, 2019, 07:00 ET Provention Bio Announces Breakthrough Therapy Designation for Teplizumab (PRV-031) for the Prevention or Delay of Clinical Type 1 Diabetes in At-Risk Individuals

Provention Bio, Inc. (Nasdaq:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease,...

Jun 13, 2019, 07:00 ET Provention Bio Announces Termination of Public Offering of Common Stock

Provention Bio, Inc. (Nasdaq: PRVB) announced today that it has terminated the public offering of common stock previously announced on June 10, 2019. ...

Jun 10, 2019, 17:32 ET Provention Bio Announces Proposed Public Offering of Common Stock

Provention Bio, Inc. (Nasdaq: PRVB) announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange...

Jun 09, 2019, 13:05 ET A Single Course of Provention's PRV-031 (Teplizumab) Delays Type 1 Diabetes Onset in High-Risk Individuals by at Least Two Years

Provention Bio, Inc. (Nasdaq:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease,...

May 08, 2019, 16:30 ET Provention Bio Reports First Quarter 2019 Financial Results

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

May 08, 2019, 16:25 ET Provention Bio Announces Top-Line Results from its Phase 1b PULSE Clinical Trial of PRV-300 in Patients with Moderate-to-Severe Ulcerative Colitis

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Apr 24, 2019, 07:00 ET Provention Bio Completes Enrollment of Phase 2a PRINCE Clinical Trial with PRV-6527 in Patients with Moderate to Severe Crohn's Disease

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Apr 09, 2019, 07:00 ET Provention Bio Initiates Phase 3 PROTECT Clinical Trial with PRV-031 (Teplizumab) in Patients with Recent Onset Type 1 Diabetes

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Apr 02, 2019, 07:00 ET Provention Bio Announces Key Additions to its Senior Management Team

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Mar 28, 2019, 07:00 ET Provention Bio Appoints Jeffrey Bluestone, PhD, to Board of Directors

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Mar 19, 2019, 16:05 ET Provention Bio Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Mar 12, 2019, 16:05 ET Provention Bio to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Tuesday, March 19, 2019

Provention Bio, Inc. (Nasdaq:PRVB), a clinical-stage biopharmaceutical company focused on preventing and intercepting immune-mediated diseases,...

Feb 13, 2019, 07:33 ET Provention Bio To Present at 8th Annual Leerink Partners Global Healthcare Conference

Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics aimed at intercepting and...

Jan 28, 2019, 07:33 ET Provention Bio Receives Notice of Allowance from United States Patent and Trademark Office for Patent on Multi-Strain Coxsackievirus B Vaccine for Preventing or Treating Type 1 Diabetes (T1D)

Provention Bio, Inc. (Nasdaq:PRVB), a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics aimed at intercepting and...

Jan 03, 2019, 07:33 ET Provention Bio Announces Publication in "Expert Review of Vaccines" Describing the Scientific Rationale for Developing a Vaccine for Type 1 Diabetes by Targeting Coxsackievirus B

Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics aimed at intercepting and...

Nov 28, 2018, 07:33 ET Provention Bio Joins the C-Path Type 1 Diabetes (T1D) Consortium

Provention Bio, Inc. (Nasdaq:PRVB), a clinical-stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel...

Nov 08, 2018, 07:33 ET Provention Bio Reports Third Quarter 2018 Financial Results and Provides Business Update

Q3 2018 and Recent Corporate Highlights: Completed $63.9 million upsized initial public offering Announced co-development agreement with Amgen and...